A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity

Background: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority. MVA85A is a candidate tuberculosis vaccine designed to enhance immunity to the existing vaccine, Bacillus Calmett...

Bibliografski detalji
Glavni autori:	Rowland, R, Brittain, N, Poulton, I, Minassian, A, Sander, C, Porter, D, Williams, N, Satti, I, Pathan, A, Lawrie, A, McShane, H
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2012

Slični predmeti

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
od: Pathan, A, i dr.
Izdano: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
od: Pathan, A, i dr.
Izdano: (2012)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
od: Whelan, K, i dr.
Izdano: (2009)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
od: Harris, S, i dr.
Izdano: (2011)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
od: Mcshane, H
Izdano: (2008)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
od: Kathryn T. Whelan, i dr.
Izdano: (2011-01-01)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
od: Harris, S, i dr.
Izdano: (2013)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
od: Thomas, Z, i dr.
Izdano: (2014)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
od: Rowland, R, i dr.
Izdano: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
od: Meyer, J, i dr.
Izdano: (2013)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
od: Mcshane, H, i dr.
Izdano: (2005)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
od: Scriba, T, i dr.
Izdano: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
od: Meyer, J, i dr.
Izdano: (2013)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
od: Harris, SA, i dr.
Izdano: (2014)

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
od: Wajja, A, i dr.
Izdano: (2024)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.
od: de Cassan, S, i dr.
Izdano: (2010)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
od: Fletcher, H, i dr.
Izdano: (2008)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
od: Wajja, A, i dr.
Izdano: (2017)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
od: Minassian, A, i dr.
Izdano: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
od: Sander, C, i dr.
Izdano: (2009)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
od: Anne Wajja, i dr.
Izdano: (2017-05-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
od: Minhinnick, A, i dr.
Izdano: (2016)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Izdano: (2011-01-01)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
od: Tameris, M, i dr.
Izdano: (2014)

Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (vol 17, pg 1066, 2010)
od: de Cassan, S, i dr.
Izdano: (2011)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
od: Michele Tameris, i dr.
Izdano: (2014-01-01)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
od: Ota, M, i dr.
Izdano: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
od: Griffiths, K, i dr.
Izdano: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
od: Griffiths, K, i dr.
Izdano: (2011)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG immunized adults vaccinated with a new tuberculosis vaccine, MVA85A (Clinical and Vaccine Immunology (2010) 17, 7, (1066-1073))
od: De Cassan, S, i dr.
Izdano: (2011)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
od: Owiafe, P, i dr.
Izdano: (2012)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
od: Tameris, M, i dr.
Izdano: (2014)

CD4 T cell response to MVA85A vaccination against Mycobacterium tuberculosis in healthy HIV-infected adults
od: Beveridge, N, i dr.
Izdano: (2011)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
od: Ota, M, i dr.
Izdano: (2011)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
od: Brookes, R, i dr.
Izdano: (2008)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
od: Satti, I, i dr.
Izdano: (2014)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
od: Mcshane, H, i dr.
Izdano: (2016)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
od: Roger H Brookes, i dr.
Izdano: (2008-08-01)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
od: Riste, M, i dr.
Izdano: (2021)

MVA85A: characterising the innate immune responses after vaccination and the effect of TLR1 levels on the acquired antigen-specific immune response
od: Kostov, M, i dr.
Izdano: (2011)